These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 2509709)
1. Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat. Wrobel J; Millen J; Sredy J; Dietrich A; Kelly JM; Gorham BJ; Sestanj K J Med Chem; 1989 Nov; 32(11):2493-500. PubMed ID: 2509709 [TBL] [Abstract][Full Text] [Related]
2. Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives. Wrobel J; Millen J; Sredy J; Dietrich A; Gorham BJ; Malamas M; Kelly JM; Bauman JG; Harrison MC; Jones LR J Med Chem; 1991 Aug; 34(8):2504-20. PubMed ID: 1908522 [TBL] [Abstract][Full Text] [Related]
4. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. Sestanj K; Bellini F; Fung S; Abraham N; Treasurywala A; Humber L; Simard-Duquesne N; Dvornik D J Med Chem; 1984 Mar; 27(3):255-6. PubMed ID: 6422042 [No Abstract] [Full Text] [Related]
5. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Simard-Duquesne N; Greselin E; Dubuc J; Dvornik D Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915 [TBL] [Abstract][Full Text] [Related]
6. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat. Kemper C; Dvornik D Proc Soc Exp Biol Med; 1986 Sep; 182(4):505-10. PubMed ID: 3090558 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of macrophage chemotaxis and peripheral nerve regeneration in normal and hyperglycemic rats by the aldose reductase inhibitor Tolrestat. Calcutt NA; McMurray HF; Moorhouse DF; Bache M; Parthasarathy S; Powell HC; Mizisin AP Exp Neurol; 1994 Aug; 128(2):226-32. PubMed ID: 8076666 [TBL] [Abstract][Full Text] [Related]
9. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Robison WG; Kador PF; Akagi Y; Kinoshita JH; Gonzalez R; Dvornik D Diabetes; 1986 Mar; 35(3):295-9. PubMed ID: 3081393 [TBL] [Abstract][Full Text] [Related]
10. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy. Sredy J; Sawicki DR; Notvest RR J Diabet Complications; 1991; 5(1):42-7. PubMed ID: 1830318 [TBL] [Abstract][Full Text] [Related]
11. Determination of tolrestat, a novel aldose reductase inhibitor, in serum and tissues. Hicks DR; Kraml M Ther Drug Monit; 1984; 6(3):328-33. PubMed ID: 6438835 [TBL] [Abstract][Full Text] [Related]
12. Tolrestat pharmacokinetics in rat peripheral nerve. Dvornik D; Millen J; Hicks DR; Kraml M J Diabetes Complications; 1994; 8(1):18-26. PubMed ID: 8167382 [TBL] [Abstract][Full Text] [Related]
13. Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: synthesis and biological activity. Tawada H; Sugiyama Y; Ikeda H; Yamamoto Y; Meguro K Chem Pharm Bull (Tokyo); 1990 May; 38(5):1238-45. PubMed ID: 2118427 [TBL] [Abstract][Full Text] [Related]